# Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

> **NCT05617820** · PHASE3 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 1050 (actual)

## Conditions studied

- Dyspareunia

## Interventions

- **DRUG:** Estradiol
- **DRUG:** Imvexxy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05617820
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 1050 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617820, "Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05617820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*